Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 8

Results For "Spain"

77 News Found

Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets
News | January 11, 2022

Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets

CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia


European Commission approves Celltrion’s Covid-19 medicine
Drug Approval | November 15, 2021

European Commission approves Celltrion’s Covid-19 medicine

The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week


PCI Pharma Services acquires LSNE for its CDMO business
News | October 13, 2021

PCI Pharma Services acquires LSNE for its CDMO business

Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle


Imfinzi plus chemotherapy tripled patient survival at 3 years
Biotech | September 20, 2021

Imfinzi plus chemotherapy tripled patient survival at 3 years

The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting


Sequent Scientific announces EUGMP approval for tablets
News | July 15, 2021

Sequent Scientific announces EUGMP approval for tablets

The company has already embarked upon significant expansion in Turkey


Glenmark’s Ryaltris nasal spray approved in Europe
News | April 27, 2021

Glenmark’s Ryaltris nasal spray approved in Europe

In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business